Overview: Delta-9-THC TestIntroduction: The Delta-9-THC Test detects Delta-9-THC, the active component of cannabis, to assess drug use or toxicity, helping guide treatment for substance abuse. Affecting 1 in 50 drug users annually, cannabis use poses diagnostic challenges due to variable detection times. Following 2023 Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines, it uses LC-MS/MS for high accuracy, supporting toxicology screening. This test is essential for diagnosis, intervention, and improving outcomes in addiction medicine.
Other Names: THC Level Test, Cannabis Detection Assay.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic reliability.
Historical Milestone: Drug testing began in the 1970s with research by Foltz, who identified THC metabolites. LC-MS/MS advancements in the 2000s by Waters improved detection, surpassing earlier GC-MS methods.
Purpose: Detects Delta-9-THC to assess cannabis use, guides counseling or detoxification, and evaluates patients with drug use history, aiming to prevent overdose.
Test Parameters: Delta-9-THC levels
Pretest Condition: No special preparation required. Collect urine, whole blood, or saliva. Report history of drug use.
Specimen: Urine (sterile container, 10-50 mL), Whole Blood (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL); 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document history of drug use. Include current medications or alcohol consumption.
Consent: Written consent required, detailing the test's purpose, toxicity risks (e.g., psychosis), and sample collection risks.
Procedural Considerations: Uses LC-MS/MS to measure Delta-9-THC, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive THC confirms use, guiding therapy. Early intervention might prevent escalation, while untreated cases lead to addiction. Negative results may require metabolite tests.
Specialist Consultation: Consult an addiction specialist for interpretation.
Additional Supporting Tests: THC metabolite test, urine drug screen, or psychological evaluation to confirm diagnosis.
Test Limitations: Reflects recent use; correlation with symptoms needed. Detection window varies by sample type.
References: SAMHSA Guidelines, 2023; Journal of Analytical Toxicology, Foltz RL, 2022.
